<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03372785</url>
  </required_header>
  <id_info>
    <org_study_id>SOS-moral</org_study_id>
    <nct_id>NCT03372785</nct_id>
  </id_info>
  <brief_title>The Success of Opening Concurrent Chronic Total Occlusion leSion to Improve Cardiac Function Trial in Patients With Multi-vessel Disease</brief_title>
  <acronym>SOS-moral</acronym>
  <official_title>The Success of Opening Concurrent Chronic Total Occlusion leSion to Improve Cardiac Function Trial in Patients With Multi-vessel Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Anzhen Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The First Affiliated Hospital of Dalian Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing Anzhen Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effect of percutaneous coronary intervention
      (PCI) on cardiac function in multi-vessel disease patients with concurrent chronic total
      occlusion (CTO) lesion.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Anticipated">January 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of myocardial viability</measure>
    <time_frame>12 months</time_frame>
    <description>Changes of myocardial viability from baseline assessed with the use of Cardiovascular Magnetic Resonance(CMR) system</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac events</measure>
    <time_frame>12 months</time_frame>
    <description>all-cause mortality, cardiac death, Stroke, first or recurrent acute myocardial infarction, recurrent angina, target lesion revascularization (TLR), heart failure, and re-hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rates of target vascular revascularization (TVR), TLR, and stent thrombosis</measure>
    <time_frame>12 months</time_frame>
    <description>Major adverse cardiac events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of left ventricular ejection fraction (LVEF)</measure>
    <time_frame>12 months</time_frame>
    <description>Changes of LVEF in % assessed with the use of cardiac MRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of myocardial infarct size</measure>
    <time_frame>12 months</time_frame>
    <description>Changes of myocardial infarct size in percentage of total myocardial size assessed with CMR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of left ventricular mass (LVM)</measure>
    <time_frame>12 months</time_frame>
    <description>Changes of left ventricular mass (LVM) in g assessed with CMR</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Chronic Total Occlusion of Coronary Artery</condition>
  <condition>Percutaneous Coronary Intervention</condition>
  <condition>Coronary Artery Disease</condition>
  <condition>Viable Myocardium</condition>
  <arm_group>
    <arm_group_label>Active Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Complete Revascularization of CTO and non-CTO lesions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional Intervention</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Non-CTO vessel revascularization</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aspirin, betaloc, atorvastatin, rosuvastatin, clopidogrel, ticagrelor</intervention_name>
    <description>Optimal medical therapy includes dual antiplatelet therapy and statins (aspirin, clopidogrel, ticagrelor, atorvastatin, rosuvastatin, betaloc). And optimal medical therapy should include adequate ventricular rate-limiting medication (i.e. Beta-blocker or rate-limiting calcium antagonist) where appropriate. Anti-anginal therapy should be used if the patients have symptom.</description>
    <arm_group_label>Active Intervention</arm_group_label>
    <arm_group_label>Conventional Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>coronary wires. stents or coronary balloons</intervention_name>
    <description>all species of drug-eluting stent ((such as Xience, Endeavor, Resolute) implantation or balloon expansion (POBA)</description>
    <arm_group_label>Active Intervention</arm_group_label>
    <arm_group_label>Conventional Intervention</arm_group_label>
    <other_name>percutaneous coronary intervention</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of stable or unstable angina

          -  LVEF &gt; 35% on transthoracic echocardiography measurement

          -  Single CTO lesion detected by angiography or CTA, with stenosis of other major
             coronary arteries (≥75% stenotic lesion)

          -  Availability for follow-up for up to 12 months

          -  No major barriers to provide written consent

        Exclusion Criteria:

          -  AMI during the latest 3 months

          -  Revascularization in the non-culprit artery during the latest 1 month

          -  Unsuitable for PCI

          -  Unable to tolerate dual antiplatelet treatment (DAPT)

          -  Severe abnormal hematopoietic system, such as platelet count of &lt; 100×109/L or &gt;
             700×109/L and white blood cell count of &lt; 3×109/L

          -  Active bleeding or bleeding tendency

          -  Severe coexisting conditions, such as severe renal insufficiency (GFR &lt; 60
             ml/min•1.73m2), severe hepatic dysfunction [elevated ALT (glutamic-pyruvic
             transaminase) or AST (glutamic-oxal acetic transaminase) level by more than three-fold
             of the normal limitation], acute or chronic heart failure (NYHA III-IV), acute
             infectious diseases, immune disorders, malignancy, etc.

          -  Life expectancy &lt; 12 months

          -  Pregnancy or planning pregnancy

          -  Drug allergies or contraindications to aspirin, clopidogrel, ticagrelor, statins,
             contract, anticoagulant, stent, etc.

          -  Participation or planning to participate in another clinical trial during the same
             period

          -  Refusal to comply with the study protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiantao Song, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University Beijing China</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2017</study_first_submitted>
  <study_first_submitted_qc>December 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2017</study_first_posted>
  <last_update_submitted>December 10, 2017</last_update_submitted>
  <last_update_submitted_qc>December 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>coronary artery disease</keyword>
  <keyword>Cardiac magnetic resonance (CMR) imaging</keyword>
  <keyword>Myocardial Stunning</keyword>
  <keyword>Percutaneous Coronary Intervention</keyword>
  <keyword>Chronic Total Occlusion of Coronary Artery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Glucuronyl glucosamine glycan sulfate</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Metoprolol</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

